Shizane's Accounts

[Shizane]

Below is a Forbes link that states Pharmaceutical companies are spending an average of $5B per new drug. At also states that focussing on "ultra-rare diseases; treatments for such ailments can cost $200,000 or more per patient per year, and be highly lucrative." It then goes on to state "BioMarin, another orphan drug maker, spent just $134 million per drug." Of course BioMarin (BMRN) is intertwined with Catalyst Pharmaceutical Partners (CPRX).




Cost of Creating a New Drug